

Grifols Egypt is accelerating self-sufficiency thanks to strong collection momentum

- *Growing plasma collections expected to double in 2024 thanks to rising donor turnout; Grifols Egypt collecting enough plasma to meet Egypt's immunoglobulin needs for the first time*
- *The very first integrated platform in Africa for sourcing and producing plasma medicines for the wider region has already dispatched more than 30,000 vials of essential therapies to hospitals*
- *Grifols Egypt about to open its 10th donor center out of the 20 planned. When the network and new manufacturing site are completed, the current workforce will reach 2,000 highly qualified jobs, triple the current staff*
- *This innovative public-private plasma initiative, alongside a similar program in Canada, is part of Grifols' growth strategy to meet the climbing global demand for plasma therapeutics*

Barcelona, Spain, Feb. 21, 2024 Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, has announced that its first-of-its kind integrated platform for sourcing and producing plasma medicines in Africa is moving energetically towards local self-sufficiency in these vital therapies.

Grifols Egypt, which expects to double plasma collections in 2024, is already receiving enough donations to meet Egypt's current domestic need for immunoglobulins (Ig).

This is a key milestone in the country's plan to reach strategic autonomy in plasma treatments. Grifols Egypt is providing increasing quantities of plasma medicines such as immunoglobulins, albumin and coagulation factors. To date more than 30,000 vials of these hemoderivatives have been delivered to Egyptian hospitals and the patients who depend on them.

Roughly two years after starting to take its first donations, Grifols Egypt is about to open its 10th center, halfway to the 20 planned locations. A total of eight centers have been certified by the Plasma Protein Therapeutic Association's International Quality Plasma Program – including four that just received this distinction – which confirms best practices through third-party audits. All will eventually have the validation.

Meantime, a new 105,000 square-meter state-of-the-art manufacturing site is taking shape in the New Administrative Capital's Medical City, featuring fractionation and purification plants, logistics facilities and what will be Grifols' very first plasma analysis lab globally to be fully automated. At peak performance, Grifols Egypt will analyze more than 1 million plasma samples annually.

GRIFOLS

Grifols Egypt's current highly qualified workforce of more than 650 direct employees is expected to more than triple to 2,000 when all 20 donor centers are up and running and the production site is fully operational. The number of specialized training hours employees have received to date, 145,000, will also shoot up significantly.

Since Grifols and Egypt's National Service Projects Organization signed their historic agreement in 2020 to establish Grifols Egypt and the first integrated platform for sourcing and producing plasma medicines in Africa and the Middle East, the project has advanced steadily, even during the pandemic.

The overall initiative forms part of Grifols' Global Plasma Self-sufficiency Program, a commitment to innovative public-private alliances to ensure sustainable, long-term supplies of plasma-derived medicines. This includes everything necessary to collect, test and safely store plasma before manufacturing it into trusted therapeutics.

Grifols also has a long-term agreement in place with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in Ig medicines through an all-Canadian donation and manufacturing capability.

"Grifols is extremely pleased to reach self-sufficiency in critical immunoglobulin medicines for Egypt, the first step toward achieving complete strategic autonomy across the broader class of plasma therapeutics," said Raimon Grifols, Grifols Chief Corporate Officer. "Grifols is establishing paradigm-changing agreements around the world that support countries and regions in their efforts to ensure their domestic populations have the plasma treatments they absolutely depend on."

"Grifols Egypt is fundamentally critical to this country's strong commitment to achieving clear plasma and healthcare leadership in Egypt, and the broader geography," said Magdy Amin, CEO Grifols Egypt. "We are an integral part of a healthier Egypt."

About Grifols Egypt for Plasma Derivatives

Grifols Egypt for Plasma Derivatives is a joint-venture company between Egypt's National Service Projects Organization and Grifols. The strategic partnership's combined expertise, technology and resources seeks to strengthen Egypt's healthcare system through achieving self-sufficiency in plasma-derived medicines while reinforcing Grifols' international expansion in the Middle East and Africa.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

GRIFOLS

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

Media contacts:

Grifols

Media Press Office

media@grifols.com

Tel. +34 93 571 00 02

Egypt

Egypt's National Service Projects Organization

Email: nspo@nspo.com.eg

Tel: +2021816946

Investors:

Grifols Investors Relations Department

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for

the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.